Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: a matching-adjusted indirect comparison
Results suggest that TALA + ENZA may provide improvements in clinical outcomes relative to OLAP + AAP and NIRA + AAP in 1 L mCRPC; however, inherent limitations associated with the complexity of the analyses must be considered.
Authors
- Di Wang (ORCID: https://orcid.org/0000-0003-0232-8862)
- Anja Haltner (ORCID: https://orcid.org/0000-0002-9829-7791)
- Alexander Niyazov (ORCID: https://orcid.org/0000-0003-1292-9661)
- Imtiaz A. Samjoo (ORCID: https://orcid.org/0000-0003-1415-8055)
- Samantha Craigie
- Jonathan Nazari (ORCID: https://orcid.org/0000-0002-4758-7588)
- Elena Castro (ORCID: https://orcid.org/0000-0002-3691-6454)
- Sarah N. Walsh (ORCID: https://orcid.org/0000-0003-2988-6506)
Institutions
- Pfizer (United States) (US)
- Hospital Universitario 12 De Octubre (ES)
- EVERSANA (Canada) (CA)
Publication Details
- Journal
- Prostate Cancer and Prostatic Diseases
- Published
- 2024-12-07
- DOI
- https://doi.org/10.1038/s41391-024-00924-x
- Citations
- 2
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.84
Funders
- Pfizer